Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645930 | 0.88 | MAPT (0.43) | KMT2AMAPTNPC1RAB9ATP53 | |
| SCHEMBL6646976 | 0.88 | MAPT (0.42) | KMT2AMAPTNPC1RAB9ATP53 | |
| SCHEMBL6648297 | 0.81 | SCN10A (0.51) | KMT2AMAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL6644201 | 0.81 | F2 (0.38) | KMT2ANPC1RAB9ASORT1 | |
| SCHEMBL6644962 | 0.80 | KMT2A (0.42) | KMT2AMAPTNPC1RAB9ATP53 | |
| SCHEMBL6643114 | 0.79 | SCN10A (0.44) | NPC1RAB9ATP53LMNA | |
| SCHEMBL6647857 | 0.79 | SCN10A (0.44) | KMT2AMAPTNPC1RAB9ATP53 | |
| SCHEMBL6644477 | 0.79 | MAPT (0.45) | MAPTKDM4ELMNA | |
| SCHEMBL6646969 | 0.76 | MAPT (0.49) | KMT2AMAPTNPC1RAB9ATP53 | |
| SCHEMBL6645223 | 0.76 | F2 (0.39) | MAPTNPC1RAB9ASORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | KMT2A 916/4885MAPT 4101/4885NPC1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.